Login

Company Executives

$ Management Team

Mr. Brian Ritchie

Investor Relations

Age -
Compensation -
Sex Male

Mr. Daniel Burgess

Independent Chairman of the Board

Age 63
Compensation $451.5K USD
Sex Male

Dr. Jeffrey Stein

President

Chief Executive Officer

Director

Age 70
Compensation $5.966M USD
Sex Male

Mr. Frank Karbe

Chief Financial Officer

Age 57
Compensation -
Sex Male

Mr. Shane Ward

Chief Operating Officer

Chief Legal Officer

Company Secretary

Age 50
Compensation $929.9K USD
Sex Male
Directors
9
serving now
Independent
8 of 9
stated in the proxy
Average tenure
5.6 years
from year joined
CEO also chairs the board
No
Daniel Burgess
Director Age On board Independent Committees Other public boards 2024 pay Source
Jeffrey Stein
70 2014
11 years
Not independent None stated Ideaya Biosciences Paid as CEO
Bonnie Bassler
63 2021
4 years
Independent None stated Royalty Pharma plc Not stated
Ryan Spencer
47 2024
1 year
Independent None stated Dynavax Technologies Corporation $85,517
Daniel Burgess
63 2014
11 years
Independent None stated None stated $451,511
Josh Resnick
50 2025
0 years
Independent None stated PepGen Inc. Not stated
Theodore R. Schroeder
70 2014
11 years
Independent None stated Phathom Pharmaceuticals, Inc. $423,511
Carin Canale-Theakston
51 2021
4 years
Independent None stated None stated $332,289
James Merson
64 2024
1 year
Independent
Nominating and Governance
None stated $88,262
Chrysa Mineo
60 2018
7 years
Independent None stated None stated $391,104

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

6 disclosed in the proxy filed Apr 25, 2025
Dr. Sandison
Amount not stated

Separation agreement with Dr. Sandison upon his separation from the Company

With Company Open in proxy
named executive officers and directors
named executive officers and directors
Amount not stated

Grants of stock options and RSUs to named executive officers and stock options to directors

With Company Open in proxy
Entities Affiliated with BVF Partners L.P.
then holder of more than 5% of our Common Stock, or entity affiliated with such holder
$ 20,000,000

Purchased 20,000 shares of Series A Preferred Stock in the April 2024 private placement

With Company Open in proxy
RA Capital Healthcare Fund, L.P.
then holder of more than 5% of our Common Stock, or entity affiliated with such holder
$ 25,000,000

Purchased 389,716 shares of Common Stock and 1,286,786 pre-funded warrants in the November 2024 private placement

With Company Open in proxy
Entities Affiliated with BVF Partners L.P.
then holder of more than 5% of our Common Stock, or entity affiliated with such holder
$ 10,000,000

Purchased 389,731 shares of Common Stock and 280,869 pre-funded warrants in the November 2024 private placement

With Company Open in proxy
directors and executive officers
directors and executive officers
Amount not stated

Separate indemnification agreements requiring the Company to indemnify directors and executive officers for certain expenses

With Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support